Alpha Teknova, Inc.
$2.91
▲
7.85%
2026-04-21 09:49:01
www.teknova.com
NGM: TKNO
Explore Alpha Teknova, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$157.01 M
Current Price
$2.91
52W High / Low
$7.48 / $1.91
Stock P/E
—
Book Value
$1.28
Dividend Yield
—
ROCE
-17.67%
ROE
-22.83%
Face Value
—
EPS
$-0.32
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
158
Beta
0.33
Debt / Equity
41.1
Current Ratio
4.58
Quick Ratio
3.64
Forward P/E
-7.23
Price / Sales
3.73
Enterprise Value
$158.05 M
EV / EBITDA
-15.6
EV / Revenue
3.9
Rating
None
Target Price
$9
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Amylyx Pharmaceuticals, Inc. | $17.57 | — | $2.03 B | — | -49.46% | -61.59% | $18.61 / $3.79 | $2.78 |
| 2. | Assertio Holdings, Inc. | $18.14 | — | $116.08 M | — | -12.35% | -28.25% | $20.45 / $8.55 | $14.63 |
| 3. | Caring Brands, Inc. | $1.25 | — | — | — | -157.44% | -2.17% | $6 / $0.06 | $0.14 |
| 4. | Evolus, Inc. | $5.08 | — | $330.5 M | — | -24.97% | 587.36% | $12.28 / $3.86 | $-0.35 |
| 5. | China SXT Pharmaceuticals, Inc. | $2.06 | — | $1.97 M | — | -17.13% | -50.3% | $1,046.98 / $1.25 | $26.16 |
| 6. | Kamada Ltd. | $8.32 | 23.76 | $479.95 M | 3% | 7.92% | 7.64% | $9.35 / $6.35 | $4.66 |
| 7. | Citius Oncology, Inc. | $0.92 | — | $77.5 M | — | -45.72% | -47.41% | $6.19 / $0.49 | $0.69 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 9.98 M | 10.45 M | 10.29 M | 9.79 M | 9.27 M | — |
| Operating Profit | -4.61 M | -4.02 M | -3.39 M | -4.96 M | -5.63 M | — |
| Net Profit | -4.76 M | -4.29 M | -3.57 M | -4.64 M | -5.72 M | — |
| EPS in Rs | -0.09 | -0.08 | -0.07 | -0.09 | -0.11 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 40.52 M | 37.74 M | 36.68 M | 41.42 M |
| Operating Profit | -16.98 M | -26.15 M | -31.2 M | -28.86 M |
| Net Profit | -17.26 M | -26.75 M | -36.78 M | -47.47 M |
| EPS in Rs | -0.32 | -0.5 | -0.69 | -0.89 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 103.58 M | 118.77 M | 128.59 M | 152.26 M |
| Total Liabilities | 34.81 M | 36.38 M | 38.55 M | 52.38 M |
| Equity | 68.78 M | 82.39 M | 90.04 M | 99.89 M |
| Current Assets | 34.51 M | 42.78 M | 45.66 M | 61.14 M |
| Current Liabilities | 7.54 M | 11.21 M | 8.88 M | 10.88 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -8.65 M | -12.39 M | -18.81 M | -27.4 M |
| Investing CF | 10.7 M | -27.27 M | -7.74 M | -28.15 M |
| Financing CF | 0.15 M | 14.89 M | 12.8 M | 10.27 M |
| Free CF | -9.79 M | -13.52 M | -26.75 M | -55.55 M |
| Capex | -1.15 M | -1.12 M | -7.93 M | -28.15 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 2.89% | -11.43% | — | — |
| Earnings Growth % | 27.28% | 22.52% | — | — |
| Profit Margin % | -70.86% | -100.26% | -114.6% | — |
| Operating Margin % | -69.27% | -85.05% | -69.67% | — |
| Gross Margin % | 19.16% | 28.07% | 42.19% | — |
| EBITDA Margin % | -51.84% | -83.37% | -62.03% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.